NASDAQ: AVLN
Avalyn Pharma Inc.CIK 0001540171 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade AVLN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Avalyn Pharma raises $316M in May IPO; Q1 loss widens 54% to $27M on clinical acceleration
5 material changes detected. Sign up free to read the summary.
Avalyn Pharma reports Q1 2026 financial results
2 material changes detected. Sign up free to read the summary.
Avalyn Pharma restructures governance for IPO, creates dual-class stock with 200M non-voting shares
4 material changes detected. Sign up free to read the summary.
Latest financial statements
From 10-Q filed Jun 3, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 22.9 | 15.3 |
| General and administrative | 5.0 | 3.4 |
| Total operating expenses | 27.9 | 18.7 |
| Operating income | (27.9) | (18.7) |
| Interest expense | 0.10 | — |
| Other income/(expense), net | 1.0 | 1.2 |
| Income tax expense/(benefit) | — | — |
| Net income | (26.9) | (17.5) |
| Basic earnings per share | (21.83) | (63.24) |
| Diluted earnings per share | (21.83) | (63.24) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 92.3 | 52.3 |
| Short-term investments | 30.8 | 86.0 |
| Prepaid expenses and other current assets | 6.9 | 5.2 |
| Total current assets | 130.0 | 143.6 |
| Property, plant and equipment, net | 1.3 | 0.8 |
| Operating lease right-of-use assets, net | 1.4 | 1.5 |
| Deferred income taxes and other assets | 3.0 | 3.0 |
| TOTAL ASSETS | 135.7 | 148.9 |
| Current liabilities: | ||
| Accounts payable | 3.1 | 3.8 |
| Current portion of operating lease liabilities | 0.5 | 0.4 |
| Accrued liabilities | 8.1 | 9.9 |
| Total current liabilities | 11.8 | 14.1 |
| Long-term debt | 14.8 | — |
| Operating lease liabilities | 1.1 | 1.2 |
| Total liabilities | 27.7 | 15.3 |
| Shareholders' equity: | ||
| Common stock | 0.02 | 0.02 |
| Capital in excess of stated value | 27.9 | 26.5 |
| Accumulated other comprehensive income (loss) | 0.01 | 0.1 |
| Retained earnings (deficit) | (292.2) | (265.4) |
| Total shareholders' equity | (264.2) | (238.7) |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 135.7 | 148.9 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (29.9) | (19.3) |
| Investing Activities: | ||
| Net cash from investing activities | 55.0 | 24.1 |
| Financing Activities: | ||
| Net cash from financing activities | 14.9 | — |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗